Evidence map›Paper›PMID 38172385›Full record

ArticleInternational journal of hematology2024

Characteristics and prognosis of patients with COVID-19 and hematological diseases in Japan: a cross-sectional study.

Daisuke Minakata, Tomoyuki Uchida, Aya Nakano, Ken Takase, Nodoka Tsukada, Hiroshi Kosugi, Eri Kawata, Takahiko Nakane, Hiroyuki Takahashi, Tomoyuki Endo and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Daisuke MinakataDivision of Hematology, Department of Medicine, Jichi Medical University, Tochigi, Japan.
Tomoyuki UchidaDepartment of Hematology, Eiju General Hospital, Tokyo, Japan.
Aya NakanoDivision of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine Tokyo, Tokyo, Japan.
Ken TakaseDepartment of Haematology, Clinical Research Centre, National Hospital Organization Kyushu Medical Centre, Fukuoka, Japan.
Nodoka TsukadaDepartment of Hematology/Oncology, Asahikawa Kosei General Hospital, Asahikawa, Japan.
Hiroshi KosugiDepartment of Hematology, Ogaki Municipal Hospital, Ogaki, Japan.
Eri KawataDepartment of Hematology, Panasonic Health Insurance Organization Matsushita Memorial Hospital, Moriguchi, Japan.
Takahiko NakaneDepartment of Hematology, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan.
Hiroyuki TakahashiDepartment of Hematology and Medical Oncology, Kanagawa Cancer Center, Kanagawa, Japan.
Tomoyuki EndoDepartment of Hematology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Satoshi NishiwakiDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Hideaki FujiwaraDepartment of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.
Akiko M SaitoClinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Toshiki I SaitoClinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Koichi AkashiDepartment of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science, Fukuoka, Japan.
Itaru MatsumuraDepartment of Hematology and Rheumatology, Faculty of Medicine, Kindai University, Osakasayama, Japan.
Kinuko MitaniDepartment of Hematology and Oncology, Dokkyo Medical University, 880, Kitakobayashi, Mibu-machi, Shimotsuga-gun, Tochigi, 321-0293, Japan. mitanik@dokkyomed.ac.jp.ORCID http://orcid.org/0000-0001-9736-9469

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Japanese Society of Hematology performed an observational cross-sectional study to clarify the morbidity, prognosis, and prognostic factors in patients with COVID-19 with hematological diseases (HDs) in Japan. The study included patients with HDs who enrolled in our epidemiological survey and had a COVID-19 diagnosis and a verified outcome of up to 2 months. The primary endpoints were characteristics and short-term prognosis of COVID-19 in patients with HDs. A total of 367 patients from 68 institutes were enrolled over 1 year, and the collected data were analyzed. The median follow-up among survivors was 73 days (range, 1-639 days). The 60-day overall survival (OS) rate was 86.6%. In the multivariate analysis, albumin ≤ 3.3 g/dL and a need for oxygen were independently associated with inferior 60-day OS rates (hazard ratio [HR] 4.026, 95% confidence interval (CI) 1.954-8.294 and HR 14.55, 95% CI 3.378-62.64, respectively), whereas 60-day survival was significantly greater in patients with benign rather than malignant disease (HR 0.095, 95% CI 0.012-0.750). Together, these data suggest that intensive treatment may be necessary for patients with COVID-19 with malignant HDs who have low albumin levels and require oxygen at the time of diagnosis.

Indexed as

COVID-19Hematologic DiseasesAlbuminsCOVID-19 TestingCross-Sectional StudiesHumansJapanOxygenPrognosisRetrospective StudiesAlbuminsOxygenCOVID-19Hematological diseaseJapanJapanese Society of Hematology

Identifiers

PMID38172385
PMCPMC10830869

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.